# Cardiovascular Morbidity During Treatment of Overactive Bladder With B3 Agonists

> **NCT02622555** · — · COMPLETED · sponsor: **Karolinska Institutet** · enrollment: 221 (actual)

## Conditions studied

- Overactive Bladder

## Interventions

- **DRUG:** Mirabegron

## Key facts

- **NCT ID:** NCT02622555
- **Lead sponsor:** Karolinska Institutet
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 221 (ACTUAL)
- **Last updated:** 2015-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02622555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02622555, "Cardiovascular Morbidity During Treatment of Overactive Bladder With B3 Agonists". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02622555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*